Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
Veracyte announced the U.S. commercial launch of the Prosigna Breast Risk of Recurrence test, available for ordering starting June 8, 2026. The test uses whole-transcriptome next-generation sequencing to predict chemotherapy benefit and quantify 10-year recurrence risk for early-stage hormone-receptor positive breast cancer patients. Recent data from the OPTIMA Phase 3 trial showed that more than two-thirds of node-positive patients who previously might have received chemotherapy can now safely avoid it based on Prosigna results.
Key figures
- Five year survival rate
- 92%
- Annual hr her2 negative cases
- 225,000
- Node positive patients avoiding chemo
- more than two-thirds
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.